Incorporated in February, 2008 viDA Therapeutics, Inc (viDA) is a spin-off company established from research conducted at the University of British Columbia and Providence Health Care Research Institute; organizations with outstanding reputations for world-class research (see Partners).
We are a private, venture-backed biopharmaceutical company committed to the discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. Our unique discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for Granzymes in the destruction and inflammation of tissues.
Our scientific founder, Dr. David Granville, is a recognized, world leader in Granzyme research. Dr. Granville and his team are responsible for generating a wide body of research in the newly emerging field of granzyme pathology, on which viDA’s intellectual property and technology is based.